Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A.

Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11.

2.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

3.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

4.

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

Hegde PS, Karanikas V, Evers S.

Clin Cancer Res. 2016 Apr 15;22(8):1865-74. doi: 10.1158/1078-0432.CCR-15-1507. Review.

5.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A.

Oncoimmunology. 2015 Jun 24;5(2):e1062969. eCollection 2016 Feb.

6.

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P.

Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9.

7.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH.

Clin Cancer Res. 2016 Feb 15;22(4):858-67. doi: 10.1158/1078-0432.CCR-15-1506. Epub 2015 Oct 7.

8.

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.

Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, Fischer OS, Moersig W, Savic Prince S, Levitsky V, Karanikas V, Lardinois D, Zippelius A.

Cancer Immunol Res. 2015 Dec;3(12):1344-55. doi: 10.1158/2326-6066.CIR-15-0097. Epub 2015 Aug 7.

9.

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.

Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD.

Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11.

10.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Mitchell PL, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie IF, Gargosky SE, Loveland BE.

J Immunother Cancer. 2014 Jun 18;2:16. doi: 10.1186/2051-1426-2-16. eCollection 2014.

11.

Foxp3 expression in liver correlates with the degree but not the cause of inflammation.

Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, Patsiaoura K, Nikolaidis P, Karanikas V, Ritis K, Germenis AE.

Mediators Inflamm. 2011;2011:827565. doi: 10.1155/2011/827565. Epub 2011 May 25.

12.

Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses.

Speletas M, Argentou N, Karanikas V, Gramoustianou ES, Mandala E, Braimi M, Matsouka P, Ritis K, Germenis AE.

Clin Immunol. 2011 May;139(2):155-63. doi: 10.1016/j.clim.2011.01.010. Epub 2011 Jan 25.

PMID:
21342791
13.

Determinants of cancer immunotherapy success.

Karanikas V, Germenis A.

Expert Rev Vaccines. 2010 Dec;9(12):1363-6. doi: 10.1586/erv.10.138. No abstract available.

PMID:
21105772
14.

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects.

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Tsougos I, Theodorou K, Georgoulias P, Gourgoulianis KI, Germenis AE.

J Exp Clin Cancer Res. 2010 Jun 4;29:64. doi: 10.1186/1756-9966-29-64.

15.

Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy.

Germenis AE, Karanikas V.

J Reprod Immunol. 2010 May;85(1):47-50. doi: 10.1016/j.jri.2010.02.002. Epub 2010 Mar 15. Review.

PMID:
20227764
16.

Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer.

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis KI, Germenis AE.

Immunol Cell Biol. 2010 Jul;88(5):575-85. doi: 10.1038/icb.2010.8. Epub 2010 Feb 9.

PMID:
20142837
17.

Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.

Karanikas V, Germenis A.

J BUON. 2009 Sep;14 Suppl 1:S153-7. Review.

18.

Anti-survivin antibody responses in lung cancer.

Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE.

Cancer Lett. 2009 Sep 18;282(2):159-66. doi: 10.1016/j.canlet.2009.03.015. Epub 2009 Apr 19.

PMID:
19380192
19.

Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.

Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI, Germenis AE.

Clin Immunol. 2008 Nov;129(2):230-40. doi: 10.1016/j.clim.2008.07.024. Epub 2008 Sep 13.

PMID:
18789878
20.

Foxp3 expression in human cancer cells.

Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE.

J Transl Med. 2008 Apr 22;6:19. doi: 10.1186/1479-5876-6-19.

21.

Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy.

Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J, Poularakis T, Gourgoulianis KI, Germenis AE.

Cancer Biol Ther. 2008 Mar;7(3):345-52. Epub 2007 Dec 13.

PMID:
18094614
22.

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer.

Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI, Germenis AE.

Cancer Biol Ther. 2007 Aug;6(8):1258-62. Epub 2007 May 17.

PMID:
17700060
23.

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Zamanakou M, Germenis AE, Karanikas V.

Immunol Lett. 2007 Aug 15;111(2):69-75. Epub 2007 Jul 2. Review.

PMID:
17644189
24.

Immunoepigenetics: the unseen side of cancer immunoediting.

Germenis AE, Karanikas V.

Immunol Cell Biol. 2007 Jan;85(1):55-9. Epub 2006 Nov 28. Review.

PMID:
17130900
25.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77.

26.

Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.

27.

Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.

Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A.

J Immunol. 2003 Nov 1;171(9):4893-7.

28.

Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.

Trautmann L, Labarrière N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie P, Bonneville M.

Eur J Immunol. 2002 Nov;32(11):3181-90.

29.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T.

Immunol Rev. 2002 Oct;188:33-42. Review.

PMID:
12445279
30.

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10290-5. Epub 2001 Aug 21.

31.

Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.

Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF.

J Immunother (1991). 2001 Mar;24(2):172-183.

PMID:
11449074
32.

A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.

Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, Coulie PG.

Cancer Res. 2001 May 15;61(10):4078-83.

33.

High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.

Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG.

Cancer Res. 2001 May 1;61(9):3718-24.

34.

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.

Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF.

J Immunother. 2001 Mar-Apr;24(2):172-83.

PMID:
11265775
35.

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz GA.

Vaccine. 2000 Aug 1;18(28):3297-309.

PMID:
10869775
36.

Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.

Karanikas V, Lodding J, Maino VC, McKenzie IF.

Clin Cancer Res. 2000 Mar;6(3):829-37.

37.
38.

Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates.

Vaughan HA, Ho DW, Karanikas VA, Ong CS, Hwang LA, Pearson JM, McKenzie IF, Pietersz GA.

Vaccine. 1999 Jun 4;17(20-21):2740-52.

PMID:
10418926
39.

Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF.

J Immunol. 1997 Dec 1;159(11):5211-8.

PMID:
9548459
40.

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.

J Clin Invest. 1997 Dec 1;100(11):2783-92.

41.

Affinity of antibodies to MUC1 antigens.

Karanikas V, Patton K, Jamieson G, Pietersz G, McKenzie I.

Tumour Biol. 1998;19 Suppl 1:71-8.

PMID:
9422091
42.

Hepatic portal infiltrates in mice immunized with syngeneic lymphoid cells: connotations for models of autoimmune liver disease.

Karanikas V, MacKay IR, Rowley MJ, Veitch B, Loveland BE.

J Gastroenterol Hepatol. 1995 Sep-Oct;10(5):491-7.

PMID:
8963023
43.

Autoreactive MHC-restricted cytotoxic cells in BALB/c mice after novel immunisation with a conserved mammalian autoantigen.

Karanikas V, Mackay IR, Rowley MJ, Loveland BE.

Cell Immunol. 1993 Apr 15;148(1):166-76.

PMID:
8495485

Supplemental Content

Loading ...
Support Center